DDInter1158 DDInter1174
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953.
Mesalazine {u} (Compound) downregulates {v} (Gene) TNIP1
TNIP1 {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Mesalazine {u} (Compound) binds {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Mesalazine {u} (Compound) upregulates {v} (Gene) MYLK
MYLK {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Mesalazine {u} (Compound) downregulates {v} (Gene) COTL1
COTL1 {u} (Gene) is downregulated by {v} (Compound) Methotrexate
Mesalazine {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Methotrexate
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may lead to a major life threatening interaction when taken with {v} Methotrexate
Mesalazine {u} (Compound) downregulates {v} (Gene) TNIP1
TNIP1 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Methotrexate
Mesalazine {u} (Compound) binds {v} (Gene) IKBKB
IKBKB {u} (Gene) is regulated by {v} (Gene) ATIC
ATIC {u} (Gene) is bound by {v} (Compound) Methotrexate
Mesalazine {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is associated with {v} (Disease) stomach cancer
stomach cancer {u} (Disease) is treated by {v} (Compound) Methotrexate
Mesalazine (Compound) downregulates TNIP1 (Gene) and TNIP1 (Gene) is upregulated by Methotrexate (Compound)
Mesalazine (Compound) binds IKBKB (Gene) and IKBKB (Gene) is upregulated by Methotrexate (Compound)
Mesalazine (Compound) upregulates MYLK (Gene) and MYLK (Gene) is upregulated by Methotrexate (Compound)
Mesalazine (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is downregulated by Methotrexate (Compound)
Mesalazine (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Methotrexate (Compound)
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may lead to a major life threatening interaction when taken with Methotrexate
Mesalazine (Compound) downregulates TNIP1 (Gene) and TNIP1 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Methotrexate (Compound)
Mesalazine (Compound) binds IKBKB (Gene) and IKBKB (Gene) is regulated by ATIC (Gene) and ATIC (Gene) is bound by Methotrexate (Compound)
Mesalazine (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is associated with stomach cancer (Disease) and stomach cancer (Disease) is treated by Methotrexate (Compound)